Ms. Otsuki has over twenty years of industry experience. She was one of the original founders of Oncternal, when the company was known as Tokalas, Inc. She was founder of Selexagen Therapeutics, a discovery stage oncology company and Senior Vice President of Commercial Development at Kanisa Pharmaceuticals, Inc, an oncology development company. In 2015, Ms. Otsuki is a co-founder of Alastin Skincare, Inc. and most recently, Precision IBD.

She was also founder and Senior Vice President of Operations at NovaCardia, a cardiovascular specialty biopharma company which was sold to Merck for $360 million and subsequently spun its second compound into Sequel Pharmaceuticals; founder and Chief Operating Officer of DexCom (DXCM); founder and held several executive management level positions Quidel Corporation (QDEL), a medical diagnostics company.